ARTICLE | Clinical News
DNDN starts Phase II Mylovenge trial
November 6, 2001 8:00 AM UTC
Dendreon (DNDN) began a U.S. Phase II trial of its Mylovenge dendritic cell cancer vaccine to treat multiple myeloma. DNDN said the trial will assess the product's ability to stimulate an immune respo...